Halozyme Therapeutics (HALO) Gains from Investment Securities: 2010-2025
Historic Gains from Investment Securities for Halozyme Therapeutics (HALO) over the last 12 years, with Sep 2025 value amounting to -$307,000.
- Halozyme Therapeutics' Gains from Investment Securities fell 107.14% to -$307,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $78.4 million, marking a year-over-year increase of 136.44%. This contributed to the annual value of $80.6 million for FY2024, which is 153.87% up from last year.
- According to the latest figures from Q3 2025, Halozyme Therapeutics' Gains from Investment Securities is -$307,000, which was up 88.14% from -$2.6 million recorded in Q2 2025.
- In the past 5 years, Halozyme Therapeutics' Gains from Investment Securities registered a high of $78.0 million during Q4 2024, and its lowest value of -$2.9 million during Q2 2024.
- For the 3-year period, Halozyme Therapeutics' Gains from Investment Securities averaged around $10.3 million, with its median value being $1.0 million (2023).
- As far as peak fluctuations go, Halozyme Therapeutics' Gains from Investment Securities skyrocketed by 2,740.83% in 2022, and later tumbled by 26,445.45% in 2024.
- Halozyme Therapeutics' Gains from Investment Securities (Quarterly) stood at $1.2 million in 2021, then soared by 2,740.83% to $33.5 million in 2022, then decreased by 8.73% to $30.5 million in 2023, then skyrocketed by 155.35% to $78.0 million in 2024, then plummeted by 107.14% to -$307,000 in 2025.
- Its Gains from Investment Securities stands at -$307,000 for Q3 2025, versus -$2.6 million for Q2 2025 and $3.3 million for Q1 2025.